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Introduction: Methicillin-resistant S. aureus (MRSA) is a common cause of bone and joint infection. BT2-peg2
-vancomycin is an investigational bone-targeted formulation of vancomycin which we hypothesized would have
increased antimicrobial activity compared to conventional vancomycin in a chronic experimental MRSA
osteomyelitis model.
Methods: We tested bone affinity using an hydroxyapatite (HA) binding assay, assessed the in vitro antimicrobial
susceptibility of 30 MRSA isolates, and compared vancomycin and BT2-peg2-vancomycin in a rat experimental
osteomyelitis model.
Results: Vancomycin did not bind to hydroxyapatite (HA binding index = 0), whereas BT2-peg2-vancomycin showed
appreciable binding (HA binding index = 57). The MIC50 was 1 μg/ml and the MIC90 was 2 μg/ml for both vancomycin
and BT2-peg2-vancomycin. The MBC90 was 16 and 4 μg/ml for vancomycin and BT2-peg2-vancomycin, respectively.
Treatment with 50 mg/kg of vancomycin every 12 hours (median, 4.73 log10 cfu/g), 63.85 mg/kg (equivalent to
50 mg/kg vancomycin) of BT2-peg2-vancomycin every 12 hours (median, 3.93 log10 cfu/g) or 63.85 mg/kg of BT2-peg2
-vancomycin once per week (median, 5.00 log10 cfu/g) was more active than no treatment (median, 5.22 log10 cfu/g)
(P =0.0481). Treatment with 63.85 mg/kg of BT2-peg2-vancomycin every 12 hours was more active than all other
treatment regimens evaluated (P≤0.0150), but was associated with high plasma BT2-peg2-vancomycin levels, decreased
animal weight, increased kidney size, creatinine and BUN, and leukocytosis with tubulointerstitial nephritis.
Conclusion: With optimization of pharmacokinetic parameters to prevent toxicity, BT2-peg2-vancomycin may be useful
in the treatment of MRSA osteomyelitis.
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Treatment of methicillin-resistant Staphylococcus aureus
(MRSA) osteomyelitis usually requires surgical débride-
ment and antimicrobial therapy. Vancomycin is often used
for the latter; optimizing systemic vancomycin dosing may
be challenging. Since osteomyelitis is a focal infection, local
delivery of antimicrobial therapy may be useful. This has* Correspondence: patel.robin@mayo.edu
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in any medium, provided the original work is pbeen done with local delivery of antimicrobial-impregnated
polymethylmethacrylate. An alternative approach would be
to formulate the antimicrobial agent such that, when deliv-
ered systemically, it targets bone.
Tetracycline binds hydroxyapatite and has been previ-
ously conjugated to other drugs, including estradiol; its
complex structure and poor stability during chemical con-
jugation limit its use as a conjugated osteotropic agent.
However, its hydroxyapatite binding domain could be spe-
cifically exploited to develop a bone-targeting agent. Using
this strategy, bone-targeted estrogen has been developed
(Neale et al. 2009).Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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moiety would theoretically yield a compound targeting
delivery of vancomycin to bone, a strategy that could be
useful in the treatment of bone infection. Pradama
Inc. has developed a bone-targeted vancomycin, BT2-
peg2-vancomycin (Figure 1) (Pierce et al. 2011). Previ-
ous studies show concentrations of BT2-peg2-vancomycin
twelve hours after a single injection (63.85 mg/kg, equiva-
lent to 50 mg/kg vancomycin) were 27.97 and 14.18 μg/ml
for plasma and bone, respectively. Concentrations of BT2-
peg2-vancomycin after seven doses given every 12 hours
were 48.21 and 75.49 μg/ml for plasma and bone, respect-
ively (Schmidt et al. 2011). The purpose of this study was
to compare the in vitro and in vivo activity of BT2-peg2-




Thirty clinical isolates of MRSA were studied. The mini-
mum inhibitory concentration (MIC) of oxacillin (Sigma-
Aldrich, St. Louis, MO), vancomycin HCl (Sigma-Aldrich),
and BT2-peg2-vancomycin diacetate containing 82.4%
vancomycin (Pradama Inc., Louisville, KY) were deter-
mined using broth microdilution according to Clinical
and Laboratory Standards Institute (CLSI) guidelines
(Clinical and Laboratory Standards Institute 2012; Clinical
and Laboratory Standards Institute 2013). The minimum
bactericidal concentration (MBC) of vancomycin HCl and
BT2-peg2-vancomycin diacetate were also determined
according to CLSI guidelines (Clinical and Laboratory
Standards Institute 1999).
Hydroxyapatite (HA) binding assay
10-5 M solutions of tetracycline, vancomycin HCl or
BT2-peg2-vancomycin diacetate in 50 mM Tris–HClFigure 1 Structure of BT2-peg2-vancomycin (C80H94Cl2N12O29, molecubuffer, pH 7.4, 1% DMSO were prepared. Tetracycline
was used as a reference analyte; at 10-5 M, approximately
50% was bound to HA. An HA slurry of 0.5 g HA/100
ml 50 mM Tris–HCl buffer, 1% DMSO was prepared.
For each analyte, two samples were tested in triplicate.
For one sample, 1 ml of 10-5 M analyte and 100 μl
50 mM Tris–HCl buffer, 1% DMSO was pipetted into
a microcentrifuge tube. For the second sample, 1 ml
of 10-5 M analyte and 100 μl of the HA slurry was
pipetted into a microcentrifuge tube. The samples
were mixed gently by inversion for five minutes and
then centrifuged at 12,000 g for three minutes to
sediment the HA. The supernatant was transferred to
another microcentrifuge tube. An electronic spectral scan
(ultraviolet–visible) from 220–520 nm was obtained for
each analyte using a Varian Cary 300 Bio Scan (Agilent
Technologies, Santa Clara, CA). The blank was 50 mM
Tris–HCl buffer, 1% DMSO. The wavelength of maximum
absorbance (λmax) was determined, and the extinction
coefficient (ε) calculated using the Beer-Lambert law.
Absorbance of the samples incubated with HA was mea-
sured at λmax, and the molar concentration of the analyte
determined using the Beer-Lambert law and the previ-
ously calculated extinction coefficient. The fraction
adsorbed to HA was calculated for each sample. The HA
binding capacity of each analyte was normalized to tetra-
cycline by calculating the HA binding index, defined as
percentage of analyte bound to HA/percentage of tetra-
cycline bound to HA × 100 (Neale et al. 2009).
In vivo studies
Experimental osteomyelitis
The experimental model described was performed in ac-
cordance with the guidelines of the Institutional Animal
Care and Use Committee of the Mayo Clinic. Experi-
mental osteomyelitis was established in 90 male Wistarlar weight: 1758.57 g/mol) (Pierce et al. 2011).
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osteomyelitis (O'Reilly & Mader 1999). In earlier studies
by our laboratory, we found that this model was highly
reproducible with histological changes similar to those
observed in humans with chronic osteomyelitis (Patel
et al. 2000; Rouse et al. 2006). Animals were anesthe-
tized with ketamine and xylazine and the proximal third
of the medial left tibia surgically exposed. A 0.5 mm hole
was drilled into the medullary cavity. Fifty microliters of
morrhuate sodium (a sclerosing agent) was injected into
the cavity, followed by 50 μl sterile saline containing 107
colony forming units (cfu) of MRSA IDRL-4293. The
muscle was reattached with coated vicryl sutures (Ethicon,
Somerville, NJ). The skin was closed with tissue glue
(Tissuemend, Butler Animal Health Supply, Dublin, OH)
and wound clips (Harvard Apparatus, Holliston, MA).
The wound was sprayed with a wound adhesive (Aluspray,
Butler Animal Health Supply, Dublin, OH), along with a
chewing repellent (Chewguard, Summit Hill Laboratories,
Tinton Falls, NJ).
Four weeks after establishing infection, five rats were
sacrificed, the left tibia aseptically removed and quantita-
tive cultures performed. The remaining animals under-
went surgical débridement of the infection site with
sterile saline and were arbitrarily assigned to one of five
study arms for a duration of 21 days: No treatment
(n=17), vancomycin HCl every 12 hours (n=17, 42
doses), BT2-peg2-vancomycin diformate every 12 hours
(n=17, 42 doses), BT2-peg2-vancomycin diformate every
12 hours for 3.5 days and then every fourth day there-
after (n=16, 11 doses), and BT2-peg2-vancomycin
diformate once per week (n=15, 3 doses). Vancomycin
HCl was administered at 50 mg/kg and BT2-peg2-
vancomycin diformate at 63.85 mg/kg (equivalent to 50
mg/kg active vancomycin); both were administered in-
traperitoneally. Twelve hours after completion of ther-
apy (day 50), blood was collected via cardiac puncture
for hematology and chemistry studies [performed by
Charles River (Wilmington, MA)], and drug concentration
studies. Rats were sacrificed with CO2. The left (infected)
tibia from one animal in each group was collected for
histopathology with bones placed in 10% neutralized buff-
ered formalin (NBF), decalcified, embedded in parafilm,
prepared as longitudinal cuts and stained with hematoxylin
and eosin. The left (infected) tibias from the remaining ani-
mals were weighed, cryopulverized and processed for
quantitative and qualitative bacterial culture. Culture re-
sults were expressed as log10 cfu/g of bone tissue.
Ten MRSA colonies per animal recovered from
quantitative bacterial cultures were tested for suscep-
tibility to BT2-peg2-vancomycin diformate and/or vanco-
mycin HCl.
Kidneys from all animals were weighed, observed for
abnormalities in size or color, and placed in NBF.Histological analysis was performed by Seventh Wave
(Chesterfield, MO). Microscopic lesions were graded on
a scale of one to four, with four being the most severe.
Tubulointerstitial nephritis was characterized by multi-
focal non-suppurative interstitial inflammation, intersti-
tial fibrosis, tubular epithelial degeneration, necrosis,
and regeneration with frequent intra-tubular neutro-
philic inflammation and cellular debris.
Three right tibias from each group were collected,
weighed, placed into NBF, and sent to Histion LLC
(Everett, WA). They underwent decalcification and
were embedded in paraffin, cut into three frontal sec-
tions, and stained with either Masson’s trichrome,
hematoxylin and eosin, or toluidine blue. Sections
were sent to Think Bone Consulting (Seattle, WA) for
histomorphometry performed using an OsteoMeasureXP
system (Osteometrics, Inc., Atlanta, GA). Bone mass and
possible toxic effects were assessed by measuring tissue
area (bone/marrow), bone area and perimeter, and perim-
eter of bone lined by osteoblasts.
Plasma concentrations of BT2-peg2-vancomycin in
infected animals were measured by liquid chromatography/
mass spectrometry (LC/MS). Plasma samples (50 μl)
were mixed with 200 μl of 25 μg/ml teicoplanin
(Sigma, St. Louis, MO) in 1% formic acid. Proteins
were precipitated with 750 μl of acetonitrile (ACN)
and centrifuged at 13,000 RPM for two minutes. The
supernatant was collected and concentrated to 50 μl
by speedvac, diluted with 100 μl 5% ACN in 0.1% for-
mic acid, loaded onto a prewashed C18 spin column
(Nest Group, Inc, Southborough, MA), washed three
times with 100 μl 5% ACN in 0.1% formic acid, and
eluted twice with 100 μl 5% ACN in 0.1% formic
acid. The elutes (50 μl) were diluted with 450 μl 5%
ACN in 0.1% formic acid and analyzed by Accela LC
System (Thermo Scientific, San Jose, CA) coupled with a
LTQ-Orbitrap XL mass spectrometer (Thermo Scientific,
San Jose, CA). Samples were loaded onto a 50 ×
2.1 mm × 1.9 μm Hypersil GOLD column (Thermo
Scientific, San Jose, CA) and eluted with a 17 minute
binary solvent gradient (solvent A: 5% ACN/0.1%
formic acid and solvent B: 95% ACN/0.1% formic
acid) at 100 μl/minute. The gradient started from 5%
solvent B, increased linearly to 80% solvent B in 12
minutes, and then remained at 80% B for 5 minutes.
Elutes from the LC column were ionized by electrospray
ionization and BT2-peg2-vancomycin and teicoplanin
were detected by multiple reaction monitoring. Full scan
fragment spectra from precursor ions (double charged
m/z 880.3 from 5.5 to 7 minutes for BT2-peg2-vanco-
mycin and double charged m/z 940.8 from 7 to 10
minutes for teicoplanin) were acquired by orbitrap.
Compound confirmation was obtained from fragment
spectra and concentration was calculated from peak
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6.25 minutes for BT2-peg2-vancomycin diformate and
m/z 1563.36 at 7.95 minutes for teicoplanin) and a
calibration curve from control rat plasma (Biochemed
Services Winchester, VA) spiked with authentic BT2-
peg2-vancomycin diformate (0 to 200 μg/ml).
Plasma concentrations of vancomycin were measured
by LC/MS. Protein precipitation and C18 spin column
cleanup were performed as described for BT2-peg2-
vancomycin diformate except that the teicoplanin con-
centration was 2.5 μg/ml and 0.1% formic acid was used
as washing solvent. Elutes from the C18 column were
concentrated to approximately 10 μl by speedvac, diluted
to 100 μl with 0.1% formic acid, and analyzed by LC/MS
with same column, gradient and instruments. Full scan
fragment spectra from precursor ions (double charged
m/z 725.7 from 0 to 5.5 minutes for vancomycin and
double charged m/z 940.8 from 7 to 10 minutes for
teicoplanin) were acquired by orbitrap. Compound con-
firmation was obtained from fragment spectra and con-
centration was calculated from peak areas of fragment ion
chromatograms (m/z 1305.34 at 5.0 minutes for vanco-
mycin and m/z 1563.36 at 7.95 minutes for teicoplanin)
and a calibration curve from control rat plasma spiked
with vancomycin standard (0 to 5 μg/ml).
Statistical methods
Descriptive summaries for bacterial culture, hematology
and chemistry studies are reported as medians and
ranges. Comparisons between groups were performed
using the Kruskall Wallis test. If the overall test among
the groups was significant, further pairwise comparisons
were made using the Wilcoxon rank-sum test. Given the
small sample sizes, no adjustments for multiple compari-
sons were made. All tests were two sided and p-values
less than 0.05 were considered statistically significant.
Statistical analysis was performed using SAS version 9.2




All isolates were resistant to oxacillin, with a MIC range
of 4 to >128 μg/ml. The oxacillin MIC for 50% of the
isolates was >128 μg/ml. The MIC at which 50% of
the isolates were inhibited (range) was 1 μg/ml (0.5
to 2 μg/ml) for both vancomycin HCl and BT2-peg2-
vancomycin diacetate. The MBC at which 50% of isolates
were killed (range) was 2 μg/ml (0.5 to 64 μg/ml) for
vancomycin HCl and 2 μg/ml (0. 5 to >128 μg/ml) for
BT2-peg2-vancomycin diacetate. The MIC at which 90%
of the isolates were inhibited was 2 μg/ml for both vanco-
mycin HCl and BT2-peg2-vancomycin diacetate. The
MBC at which 90% of isolates were killed was 16 and 4μg/ml for vancomycin HCl and BT2-peg2-vancomycin
diacetate, respectively.
HA binding assay
The bone-targeting capacity of vancomycin HCl and
BT2-peg2-vancomycin diacetate was evaluated in vitro
using an HA binding assay. For comparative purposes
tetracycline was included as a control and was defined
as having an HA binding index of 100. Vancomycin HCl
did not bind to HA (HA binding index = 0), whereas
BT2-peg2-vancomycin diacetate showed appreciable
binding to hydroxyapatite (HA binding index = 57). This
suggests that vancomycin does not attach to HA but
that it is the bone-targeting moiety which is attached
to the parent vancomycin molecule by polyethelene
glycol linkage (Figure 1) which is responsible for




The MIC/MBC of the MRSA isolate used in the experi-
mental osteomyelitis model was 2/2 μg/ml for both
vancomycin HCl and BT2-peg2-vancomycin diformate.
Three of the 85 rats did not survive the débridement
process. Five were excluded due to Proteus sp. culture
contamination and one due to procedure error. The five
control rats showed a median of 5.56 (range, 5.25 to
5.93) log10 cfu/g of bone after the 28 day infection
period.
The percent change in body weight over the course of
21 days of treatment for each treatment group is shown
in Figure 2. The terminal body weights of the animals
treated with BT2-peg2-vancomycin diformate every 12
hours were statistically lower than those of each of the
other treatment groups (P<0.0001). The bone specimens
reviewed from one animal in each group were confirmed
to have histological features consistent with osteomye-
litis (Vigorita 2008). An acute inflammatory response
along with microabscess formation was observed in all
specimens.
Results of quantitative cultures are shown in Figure 3.
The untreated group had a median of 5.22 (range, 4.37
to 6.08) log10 cfu/g of bone. The vancomycin HCl group
had a median of 4.73 (range 3.69 to 5.41) log10 cfu/g of
bone. The median was 3.93 (range, 0.80 to 4.66) log10
cfu/g of bone in the BT2-peg2-vancomycin diformate
every 12 hours group, 5.19 (range, 4.02 to 5.54) log10
cfu/g of bone in the BT2-peg2-vancomycin diformate
every 12 hours for 3.5 days then every fourth day group,
and 5.00 (range, 3.33 to 5.70) log10 cfu/g of bone in the
BT2-peg2-vancomycin diformate once per week group.
The bacterial loads in the animals treated with vanco-
mycin HCl twice daily, BT2-peg2-vancomycin diformate
Figure 2 Percent body weight change over the 21 day course of treatment. The difference between BT2-peg2-vancomycin diformate (BTV)
administered every 12 hours and each of the other treatment groups was statistically significant (P<0.0001) at time of sacrifice.
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those in the untreated animals (P=0.0037, P<0.0001,
P=0.0481 , respectively). The bacterial load in the animals
treated with BT2-peg2-vancomycin diformate twice
daily was lower than in the no treatment, twice dailyFigure 3 Results of the quantitative bone cultures showing
median values for each treatment group. The difference between
BT2-peg2-vancomycin diformate (BTV) every 12 hours (q12 h) and
each of the other groups was statistically significant (P≤ 0.0150).
(BTV q12 h 3.5 d, q4 d, treatment twice daily for 3.5 days and then
once every 4 days; BTV q1 wk, treatment once per week).vancomycin, BT2-peg2-vancomycin diformate every
12 hours for 3.5 days then every fourth day and
BT2-peg2-vancomycin once weekly groups (P<0.0001,
P=0.0150, P<0.0001 and P=0.0034, respectively).
Vancomycin MIC values of the MRSA recovered
from the untreated group were 1 to 2 μg/ml and
from the vancomycin HCl-treated animals were 2 to
4 μg/ml. Isolates recovered from BT2-peg2-vancomycin
diformate-treated animals were tested for susceptibil-
ity to both vancomycin and BT2-peg2-vancomycin. Iso-
lates from those treated with BT2-peg2-vancomycin
diformate twice daily had vancomycin and BT2-peg2-
vancomycin MICs of 1 to 4 μg/ml. Isolates from those
treated with BT2-peg2-vancomycin diformate twice daily
for 3.5 days and then once every fourth day had vanco-
mycin MICs of 1 to 2 μg/ml and BT2-peg2-vancomycin
MICs of 1 to 4 μg/ml. Isolates from those treated with
BT2-peg2-vancomycin diformate once weekly had vanco-
mycin and BT2-peg2-vancomycin MICs of 1 to 2 μg/ml.
No increase in vancomycin or BT2-peg2-vancomycin
MIC of more than one doubling dilution was observed.
Bone histology/histomorphometry of the three right
tibias from each group showed no changes in bone mass
of the treated versus the untreated animals (P<0.05).
Myelosuppression was not observed in any treatment
group.
The kidneys of the untreated and the vancomycin
HCl-treated animals had a deep maroon color and size
consistent with body weight. The kidneys from the
Table 1 Kidney weights, creatinine, BUN and albumin















1.4 (1.1-1.7) 0.5 (0.4-0.6) 18.5 (15–21) 3.4 (3.1-3.6)
BTV twice
daily
4.1 (2.4-6.0) 1.5 (1.2-2.2) 76.5 (56–114) 2.8 (2.6-3.0)
BTV twice daily
for 3.5 days and
then every
four days
1.7 (1.3-2.2) 0.6 (0.5-1.2) 31 (22–47) 3.6 (3.1-4)
BTV once per 1.5 (1.4-1.8) 0.5 (0.4-0.6) 19 (17–21) 3.6 (3.3-3.8)
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hours for 21 days were lighter in color and larger
than those of the animals in the other treatment
groups (Figure 4). Kidney weights are shown in
Table 1. Tubulointerstitial nephritis was observed in
animals treated with BT2-peg2-vancomycin diformate
and increased in incidence and severity with increasing
frequency of administration of BT2-peg2-vancomycin
diformate. In the group given BT2-peg2-vancomycin
diformate every 12 hours, the findings were histologically
severe (grade 4) and were associated with azotemia
[increased creatinine and blood urea nitrogen (BUN)]
and leukocytosis. In the group given BT2-peg2-vanco-
mycin diformate twice daily for 3.5 days and every
fourth day thereafter, the histology showed moderate
tubulointerstitial nephritis (grades 2–4) and the onceFigure 4 a. Kidney following no treatment (~19.0 × 12.5 mm);
b. kidney following treatment with BT2-peg2-vancomycin
diformate twice daily for 21 days (~25.5 × 17.5 mm).
weekweekly-treated group had mild tubulointerstitial neph-
ritis (grades 1–2). The kidneys from the untreated
and vancomycin HCl-treated groups did not exhibit
microscopic abnormalities.
In the group given BT2-peg2-vancomycin diformate
every 12 hours, the median creatinine (range) was ele-
vated at 1.5 (1.2 to 2.2) mg/dl (normal creatinine range
0.4 to 0.7 mg/dl), the median (range) BUN was elevated
at 77 (56 to 114) mg/dl (normal BUN 9–30 mg/dl)
and the median (range) serum albumin was decreased
at 2.8 (2.6 to 3.0) g/dl (normal range 3.2 to 4.5 g/dl)
(Table 1). Creatinine, BUN, and albumin were statisti-
cally significantly different in this group compared to
all the other groups (P<0.0001). In the group given
BT2-peg2-vancomycin diformate twice daily for 3.5
days and every fourth day thereafter, the median
(range) creatinine and BUN were 0.6 (0.5 to 1.2) and
31 (22 to 47) mg/dl which was higher than that in
the no treatment, vancomycin HCl-treated or BT2-
peg2-vancomycin diformate once weekly-treated ani-
mals (P<0.0001).
In the group given BT2-peg2-vancomycin diformate
every 12 hours, the median (range) total white cell count
was 34.75 (25.04 to 49.82, normal range 3.66 to
16.05) × 103/μl, neutrophil count was 20.89 (16.92 to
30.05, normal range 1.02 to 6.63) × 103/μl, eosinophil
count was 1.13 (0.26 to 10.92, normal range 0.01 to
0.51) × 103/μl, and basophil count was 0.21 (0.06 to
0.41, normal range 0.00 to 0.15) × 103/μl, all higher
than in the other groups (P<0.0001).
The median (range) plasma concentration of vanco-
mycin 12 hours after the last injection in the twice daily
vancomycin HCl treated animals was 0.71 (0.24 to
2.00) μg/ml (Table 2). The median (range) plasma
concentration of BT2-peg2-vancomycin 12 hours after the
last injection in the twice daily BT2-peg2-vancomycin
Table 2 Plasma concentrations (μg/ml) of vancomycin or
BT2-peg2-vancomycin (BTV) in the osteomyelitis animals
following 21 days of treatment




16 0.71 0.24-2.00 12
BTV twice
daily
13 129.98 74.56-207.90 12
BTV twice daily
for 3.5 days and
then every
four days
14 0.88 0.00-4.14 48
BTV once
per week
15 0.00 0.00-0.34 168
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207.90) μg/ml. The median (range) plasma concen-
tration of BT2-peg2-vancomycin 48 hours after the
last injection in the animals treated with BT2-peg2-
vancomycin diformate every 12 hours for 3.5 days
and every fourth day thereafter was 0.88 (0.00 to
4.14) μg/ml. The median (range) plasma concentra-
tion of BT2-peg2-vancomycin seven days after the
last injection in the animals treated once per week
with BT2-peg2-vancomycin diformate was 0.00 (0.00
to 0.34) μg/ml.
Discussion
BT2-peg2-vancomycin is a novel formulation of vanco-
mycin designed to target bone. We have demonstrated
that it has similar in vitro activity to vancomycin against
MRSA, indicating that BT2-peg2 formulation does not
affect the antimicrobial activity of vancomycin. We have
additionally shown that the addition of the bone-
targeting moiety to vancomycin enhances its in vitro
ability to bind to the mineral constituent of bone. Re-
sults of pharmacokinetic studies also support targeting
of bone; however, this is not without presence of BT2-
peg2-vancomycin in plasma.
Results of treatment of experimental osteomyelitis
with equivalent amounts of vancomycin at the same
dosing interval show that BT2-peg2-vancomycin
diformate is more active than vancomycin. However, this
dosing schedule of BT2-peg2-vancomycin diformate is
associated with high plasma BT2-peg2-vancomycin
levels and toxicity, manifest as decreased animal weight,
and increased kidney size with increased creatinine and
BUN, and leukocytosis in the context of histopathologic
severe tubulointerstitial nephritis. The high serum con-
centrations of BT2-peg2-vancomycin likely relates to
pegylation of the parent drug which is known to increase
drug half-life (Hamidi et al. 2006), and may alter elimin-
ation of drug from the body and biodistribution.Alternatively, the high serum BT2-peg2-vancomycin
levels may be caused by binding, retention and/or subse-
quent release of BT2-peg2-vancomycin from the bone
over time. In experimental osteomyelitis, BT2-peg2-
vancomycin diformate administered weekly yielded simi-
lar results to twice daily doses of vancomycin, without
the toxicity observed with twice daily dosing.
A limitation of this study is the dosing interval of
vancomycin HCl was selected to match that of BT2-
peg2-vancomycin, resulting in low vancomycin trough
concentrations in the vancomycin HCl treated animals.
Ideally, vancomycin HCl should have been dosed more
frequently to mimic in human levels.
Overall, results of this study indicate that BT2-peg2-
vancomycin deserves further evaluation as a bone-
targeted formulation of vancomycin with less frequent
dosing required than conventional vancomycin, and
careful assessment of plasma vancomycin levels and as-
sociated toxicity required.
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